Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

YARS2 anticorps (C-Term)

YARS2 Reactivité: Humain WB, IHC (p) Hôte: Lapin Polyclonal RB14936 unconjugated
N° du produit ABIN1882153
  • Antigène Voir toutes YARS2 Anticorps
    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))
    Épitope
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 399-427, C-Term
    Reactivité
    • 22
    • 11
    • 5
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    Humain
    Hôte
    • 21
    • 1
    Lapin
    Clonalité
    • 22
    Polyclonal
    Conjugué
    • 15
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp YARS2 est non-conjugé
    Application
    • 14
    • 5
    • 4
    • 4
    • 3
    • 2
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Homologie
    M, Rat
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogène
    This YARS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 399-427 amino acids from the C-terminal region of human YARS2.
    Clone
    RB14936
    Isotype
    Ig Fraction
    Top Product
    Discover our top product YARS2 Anticorps primaire
  • Indications d'application
    WB: 1:1000. IHC-P: 1:10~50
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Date de péremption
    6 months
  • Riley, Menezes, Rudinger-Thirion, Duff, de Lonlay, Rotig, Tchan, Davis, Cooper, Christodoulou: "Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia." dans: Orphanet journal of rare diseases, Vol. 8, pp. 193, (2014) (PubMed).

    Riley, Cooper, Hickey, Rudinger-Thirion, McKenzie, Compton, Lim, Thorburn, Ryan, Giegé, Bahlo, Christodoulou: "Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome." dans: American journal of human genetics, Vol. 87, Issue 1, pp. 52-9, (2010) (PubMed).

    Bonnefond, Frugier, Touzé, Lorber, Florentz, Giegé, Sauter, Rudinger-Thirion: "Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features." dans: Structure (London, England : 1993), Vol. 15, Issue 11, pp. 1505-16, (2007) (PubMed).

  • Antigène
    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))
    Autre désignation
    YARS2 (YARS2 Produits)
    Synonymes
    anticorps 2210023C10Rik, anticorps tyrRS, anticorps CGI-04, anticorps RGD1311696, anticorps MLASA2, anticorps MT-TYRRS, anticorps TYRRS, anticorps tyrosyl-tRNA synthetase 2 (mitochondrial), anticorps tyrosyl-tRNA synthetase 2, anticorps Yars2, anticorps YARS2
    Sujet
    YARS2 catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
    Poids moléculaire
    53199
    NCBI Accession
    NP_001035526
    UniProt
    Q9Y2Z4
Vous êtes ici:
Support technique